Drug Resistance

Tomasetti, Cristian

doi:10.1007/978-1-4939-2095-2_15

Cited by 7 publications

(5 citation statements)

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Overcoming the emergence of drug-resistance or combatting persistence cells (persisters) is a major challenge in DD. 201 – 204 Kohanski et al discussed the different drug resistant mechanisms from a biological network viewpoint. 205 Liu et al made an in silico investigation to study intrinsic and induced drug resistance mechanism in solid tumor by bridging the gap between cell and tissues.…”

Section: Antimicrobial and Drug Resistancementioning

confidence: 99%

Synthetic biology for pharmaceutical drug discovery

Trosset¹,

Carbonell²

2015

DDDT

View full text Add to dashboard Cite

Synthetic biology (SB) is an emerging discipline, which is slowly reorienting the field of drug discovery. For thousands of years, living organisms such as plants were the major source of human medicines. The difficulty in resynthesizing natural products, however, often turned pharmaceutical industries away from this rich source for human medicine. More recently, progress on transformation through genetic manipulation of biosynthetic units in microorganisms has opened the possibility of in-depth exploration of the large chemical space of natural products derivatives. Success of SB in drug synthesis culminated with the bioproduction of artemisinin by microorganisms, a tour de force in protein and metabolic engineering. Today, synthetic cells are not only used as biofactories but also used as cell-based screening platforms for both target-based and phenotypic-based approaches. Engineered genetic circuits in synthetic cells are also used to decipher disease mechanisms or drug mechanism of actions and to study cell–cell communication within bacteria consortia. This review presents latest developments of SB in the field of drug discovery, including some challenging issues such as drug resistance and drug toxicity.

show abstract

Section: Antimicrobial and Drug Resistancementioning

confidence: 99%

Synthetic biology for pharmaceutical drug discovery

Trosset¹,

Carbonell²

2015

DDDT

View full text Add to dashboard Cite

show abstract

“…Many "biological drugs" based upon a strong rationale related to the understanding of well-defined pathological mechanisms are now available for clinical oncologists [18,19]. Promising or even excellent results have been obtained in some types of tumors.…”

Section: Tuning Human Cancer Stem Cell Dynamics With Chemical Agents:mentioning

confidence: 99%

“…Promising or even excellent results have been obtained in some types of tumors. However, used individually or in combination with a more conventional treatment, such approaches so far have not substantially improved the prognosis of most types of advanced-stage tumors [18,19].…”

Section: Tuning Human Cancer Stem Cell Dynamics With Chemical Agents:mentioning

confidence: 99%

Cancer Stem Cells: Foe or Reprogrammable Cells for Efficient Cancer Therapy?

Ventura¹,

Olivi²,

Cavallini³

et al. 2015

NanoWorld J

View full text Add to dashboard Cite

Embryonic development and carcinogenesis share many molecular pathways and regulatory molecules. While the induction of a pluripotent state involves a significant oncogenic risk, as in induced pluripotent stem cells (iPSCs), the embryonic environment in vivo has been shown to suppress tumor development. In this review, we discuss the subtle equilibrium between the nanotopography (niche) of the hosting tissue resident stem cells and their biological dynamics, including the transformation in cancer stem cells. We review consistent findings indicating the potential for modulating the biology of human cancer stem cells by the aid of naturally occurring or synthetic molecules, including developmental stage zebrafish embryo extracts, hyaluronan, butyric acid (BA) and retinoic acid (RA), hyaluronan mixed esters of BA and RA, melatonin, vitamin D3, and endorphin peptides. Within this context, we dissect the multifaceted mechanisms orchestrated by endorphinergic systems, including paracrine cellto-cell communication, as well as the establishment of autocrine and intracrine (intracellular) peptide actions driving transcriptional responses and self-sustaining loops that behave as long-lived signals imparting features characteristic of differentiation, growth regulation and cell memory.Based upon the remarkable action of electromagnetic fields and mechanical vibration on (stem) cell signaling, differentiation, and senescence, we also consider the potential for using these physical energies as a tool to afford a fine tuning of cancer stem cell fate.On the whole, we forecast future deployment of the physical and/or chemical approaches described herein aiming at reprogramming, rather than destroying cancer stem cells, eventually placing cancer therapy within the context of Regenerative Medicine.

show abstract

“…Historically, hematological neoplasms have been treated with conventional chemotherapy drugs and, more recently, with combined therapies. However, despite the broad number of therapeutic options available, many treatments eventually generate partial or total resistance in many patients, leading to drug insensitivity in cancer cells and, consequently, treatment ineffectiveness [ 4 ]. In an attempt to elucidate the cellular and molecular mechanisms underlying the process of resistance to therapy, numerous investigations have identified potential therapeutic targets in multiple cellular functions [ 5 ].…”

Section: Introductionmentioning

confidence: 99%

Autophagy in Hematological Malignancies

Ruiz

Sánchez-Maldonado

Nevot

et al. 2022

Cancers

View full text Add to dashboard Cite

Autophagy is a highly conserved metabolic pathway via which unwanted intracellular materials, such as unfolded proteins or damaged organelles, are digested. It is activated in response to conditions of oxidative stress or starvation, and is essential for the maintenance of cellular homeostasis and other vital functions, such as differentiation, cell death, and the cell cycle. Therefore, autophagy plays an important role in the initiation and progression of tumors, including hematological malignancies, where damaged autophagy during hematopoiesis can cause malignant transformation and increase cell proliferation. Over the last decade, the importance of autophagy in response to standard pharmacological treatment of hematological tumors has been observed, revealing completely opposite roles depending on the tumor type and stage. Thus, autophagy can promote tumor survival by attenuating the cellular damage caused by drugs and/or stabilizing oncogenic proteins, but can also have an antitumoral effect due to autophagic cell death. Therefore, autophagy-based strategies must depend on the context to create specific and safe combination therapies that could contribute to improved clinical outcomes. In this review, we describe the process of autophagy and its role on hematopoiesis, and we highlight recent research investigating its role as a potential therapeutic target in hematological malignancies. The findings suggest that genetic variants within autophagy-related genes modulate the risk of developing hemopathies, as well as patient survival.

show abstract

Drug Resistance

Cited by 7 publications

References 47 publications

Synthetic biology for pharmaceutical drug discovery

Synthetic biology for pharmaceutical drug discovery

Cancer Stem Cells: Foe or Reprogrammable Cells for Efficient Cancer Therapy?

Autophagy in Hematological Malignancies

Contact Info

Product

Resources

About